Insmed Inc Market Cap ($24.01 Billion)
Market Cap & Net Worth: Insmed Inc (INSM)
Insmed Inc market cap. Insmed Inc (NASDAQ:INSM) has a market capitalization of $24.01 Billion ($24.01 Billion) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #1081 globally and #462 in its home market, demonstrating a 18.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Insmed Inc's stock price $112.58 by its total outstanding shares 213273469 (213.27 Million).
Insmed Inc Market Cap History (2015–2026)
Insmed Inc market cap history from 2015 to 2026. Data shows growth from $3.87 Billion to $24.01 Billion (18.06% CAGR). Check current stock price of Insmed Inc for real-time trading data and today's change.
Index Memberships
Insmed Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.92% | #18 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.06% | #134 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 1.31% | #12 of 263 |
Weight: Insmed Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Insmed Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Insmed Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see INSM operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
40.48x
Insmed Inc's market cap is 40.48 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $2.80 Billion | $9.84 Million | -$324.28 Million | 284.51x | N/A |
| 2019 | $5.09 Billion | $136.47 Million | -$254.34 Million | 37.32x | N/A |
| 2020 | $7.10 Billion | $164.41 Million | -$294.09 Million | 43.18x | N/A |
| 2021 | $5.81 Billion | $188.46 Million | -$434.65 Million | 30.83x | N/A |
| 2022 | $4.26 Billion | $245.36 Million | -$481.53 Million | 17.37x | N/A |
| 2023 | $6.61 Billion | $305.21 Million | -$749.57 Million | 21.66x | N/A |
| 2024 | $14.72 Billion | $363.71 Million | -$913.77 Million | 40.48x | N/A |
Competitor Companies of INSM by Market Capitalization
Companies near Insmed Inc in the global market cap rankings as of October 31, 2026. See Insmed Inc balance sheet independence to understand what proportion of total assets are financed by equity.
Key companies related to Insmed Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Insmed Inc (2015–2026)
Market capitalization of Insmed Inc from 2015 to today. Between 2015 and today, Insmed Inc's market cap moved from $3.87 Billion to $ 24.01 Billion, with a yearly change of 18.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $24.01 Billion | -35.31% |
| 2025 | $37.12 Billion | +152.09% |
| 2024 | $14.72 Billion | +122.78% |
| 2023 | $6.61 Billion | +55.11% |
| 2022 | $4.26 Billion | -26.65% |
| 2021 | $5.81 Billion | -18.17% |
| 2020 | $7.10 Billion | +39.41% |
| 2019 | $5.09 Billion | +82.01% |
| 2018 | $2.80 Billion | -57.92% |
| 2017 | $6.65 Billion | +135.68% |
| 2016 | $2.82 Billion | -27.11% |
| 2015 | $3.87 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Insmed Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.01 Billion USD |
| MoneyControl | $24.01 Billion USD |
| MarketWatch | $24.01 Billion USD |
| marketcap.company | $24.01 Billion USD |
| Reuters | $24.01 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Insmed Inc
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antiba… Read more